TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16400897
Drug: Budesonide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (400 microg daily)
Study: 12468570
Drug: Ramipril (escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (escalated to 10 mg/d)
Study: 12468570
Drug: Losartan (escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (escalated to 100 mg/d)
Study: 326261
Drug: Piprozoline (Problin)
Normalized name: piprozoline
DrugBank: Piprozolin (DB13202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piprozoline (Problin) therapy
Study: 22582872
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg Loperamide (LOP)
Study: 22582872
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg Loperamide (LOP) + 125 mg Simethicone (SIM)
Study: 17538178
Drug: Emerging technologies
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerging technologies for detection, characterization, and treatment of colorectal cancer
Study: 7842199
Drug: Inhaled bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bronchodilator (isoproterenol)
Study: 2240505
Drug: Trimeprazine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimeprazine 1.0 mg/kg, droperidol 0.15 mg/kg, methadone 0.08 mg/kg
Study: 319938
Drug: Guanabenz (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanabenz (2, 6‐dichlorobenzylidene aminoguanidine acetate) 4 to 16 mg twice daily
Study: 29242250
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg/m2 intravenously on days 1, 4, 8, and 11, n=21)
Study: 26854669
Drug: Insulin combined
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin combined with metformin
Study: 23968339
Drug: D. farinae
Normalized name: D. farinae extract 6 SQ-HDM / D. pteronyssinus extract 6 SQ-HDM Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: D. farinae drops plus pharmacotherapy (treatment group)
Study: 23968339
Drug: Only pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only pharmacotherapy (control group)
Study: 17557339
Drug: Nonpharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpharmacological therapy
Study: 11518845
Drug: Lacidipine (4-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (4-6 mg/daily)
Study: 11518845
Drug: Atenolol (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50-100 mg/daily)
Study: 10205435
Drug: Cabbage leaf
Normalized name: cabbage leaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabbage leaf extract cream
Study: 10205435
Drug: Feeding (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feeding (not a cream intervention)
Study: 8172501
Drug: Early, intensive,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early, intensive, supervised rehabilitation program (9 treatments combined with home exercises)
Study: 8172501
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no specific physiotherapy treatment, only instructions and prescribed exercises)
Study: 2974259
Drug: Epidural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural dexamethasone (4 mg)
Study: 2974259
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroid (group T)
Study: 29115200
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g high‐molecular weight (HMW) barley β‐glucan
Study: 18649561
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no topical fluoride agents)
Study: 10833093
Drug: UDCA (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (600 mg/day) in addition to alpha‐IFN (3 MU three times weekly)
Study: 7535512
Drug: Topical tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tretinoin (0.1%)
Study: 2455154
Drug: Lisinopril (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20-80 mg, median 40 mg)
Study: 2455154
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard (40-80 mg, median 60 mg)
Study: 30197501
Drug: Canrenone 50
Normalized name: canrenone
DrugBank: Canrenone (DB12221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenone 50 mg once a day for 1 month, then 100 mg once a day for 12 months
Study: 30197501
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg once a day for 1 month, then 25 mg once a day for 12 months
Study: 26747458
Drug: Chitosan (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan (500 mg, five/day)
Study: 24480637
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg pilsicainide hydrochloride
Study: 24480637
Drug: 0.50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg/kg pilsicainide hydrochloride
Study: 24480637
Drug: 0.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/kg pilsicainide hydrochloride
Study: 20800632
Drug: ND-CCK (Normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: ND-CCK (Normal Diet with CCK-8 infusion)
Study: 20800632
Drug: HFD-CCK (High-Fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFD-CCK (High-Fat Diet with CCK-8 infusion)
Study: 20800632
Drug: ND-SAL (Normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: ND-SAL (Normal Diet with saline infusion)
Study: 11790641
Drug: Sertraline (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (exact dosage and duration not specified)
Study: 410296
Drug: Continuous radiation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous radiation therapy with hydroxyurea
Study: 31784442
Drug: Intradermal thumbtack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal thumbtack needle group (P6 intradermal needle)
Study: 31784442
Drug: Intradermal thumbtack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal thumbtack needle group
Study: 26875887
Drug: Analgesic, anti-inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic, anti-inflammatory drugs + functional rehabilitation training
Study: 22074188
Drug: Linezolid (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (2 mg/ml) + heparin (2000 U/ml)
Study: 22074188
Drug: Vancomycin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (5 mg/ml) + heparin (2000 U/ml)
Study: 22074188
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (2000 U/ml) alone
Study: 19349549
Drug: AC-T-H (doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC-T-H (doxorubicin, cyclophosphamide, weekly paclitaxel, and trastuzumab)
Study: 19349549
Drug: AC-TH-H (doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC-TH-H (doxorubicin, cyclophosphamide, weekly paclitaxel, and trastuzumab)
Study: 19349549
Drug: AC-T (doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC-T (doxorubicin, cyclophosphamide, and weekly paclitaxel)
Study: 15356676
Drug: 4-aminopyridine (4-AP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine (4-AP), 40 mg/day, oral medication for 2 weeks
Study: 15356676
Drug: Placebo, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral medication for 2 weeks
Study: 11994699
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy with birch pollen extract
Study: 2530019
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion (37 pmol min-1 kg-1)
Study: 765873
Drug: High intravenous
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intravenous doses of methylprednisolone (1 g intravenously on alternate days, maximum of four injections)
Study: 765873
Drug: Increased daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased daily prednisolone doses (300 mg first day, 200 mg second day, 100 mg third day, tapering down over weeks)
Study: 765873
Drug: High intravenous
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intravenous doses of methylprednisolone
Study: 31325336
Drug: Antral Follicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antral Follicle Count (AFC) based gonadotropin dosing
Study: 31325336
Drug: Serum Anti-Müllerian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum Anti-Müllerian Hormone (AMH) based gonadotropin dosing
Study: 31325336
Drug: AFC based
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFC based gonadotropin dosing
Study: 31325336
Drug: AMH based
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMH based gonadotropin dosing
Study: 21614811
Drug: p16INK4a immunodetection
Approvals — FDA: no, EMA: no, PMDA: no
Description: p16INK4a immunodetection using antibody clone E6H4
Study: 15579798
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg recombinant human GHRH-1,44-amide s.c. twice daily for 3 months
Study: 15579798
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg recombinant human GHRH-1,44-amide s.c. twice daily for 3 months
Study: 8123837
Drug: Ki-67 monoclonal
Normalized name: KI
DrugBank: Potassium Iodide (DB06715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ki-67 monoclonal antibody (MoAb) treatment
Study: 331835
Drug: Oxprenolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (80 mg three times a day)
Study: 31521543
Drug: High left
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High left sided treatment
Study: 25455414
Drug: 600 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/kg iodine load and 120 kVp tube voltage setting (600-120 group)
Study: 25455414
Drug: 500 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/kg iodine load and 80 kVp (500-80 group)
Study: 25455414
Drug: 400 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/kg iodine load and 80 kVp (400-80 group)
Study: 15165935
Drug: Tezosentan (endothelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezosentan (endothelin receptor antagonist)
Study: 11524895
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment programs
Study: 11524895
Drug: Parental involvement
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental involvement in therapy
Study: 8986944
Drug: Prolonged therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged therapy group (5 MU tiw for a further 26 weeks)
Study: 8986944
Drug: Brief therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief therapy group (stopped interferon)
Study: 8986944
Drug: Prolonged therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged therapy group
Study: 8986944
Drug: Brief therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief therapy group
Study: 8247317
Drug: tolrestat (aldose
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolrestat (aldose reductase inhibitor)
Study: 21544086
Drug: 8-week dietary
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week dietary intervention (A142V polymorphism CC and CT group)
Study: 12514146
Drug: Sevoflurane 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane 2% with propofol 2 mg x kg(‐1) (Group I)
Study: 10393599
Drug: 6 to
Normalized name: vitamin B6 Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 to 10 puffs of albuterol via MDI with spacer (n = 30)
Study: 10393599
Drug: 2 puffs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 puffs of albuterol via MDI with spacer (n = 30)
Study: 10393599
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg of albuterol via nebulizer (n = 30)
Study: 2865145
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg eight-hourly
Study: 19317161
Drug: Yiqi Wenyang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Wenyang Huoxue Recipe (YWHR) given daily for 10 days
Study: 10850507
Drug: Prophylactic indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic indomethacin (0.1 mg/kg, administered within the first 24 hours of life, repeated every 24 hours for 6 doses)
Study: 10850507
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered within the first 24 hours of life, repeated every 24 hours for 6 doses)
Study: 1361781
Drug: Ciprofloxacin 25
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 25 mg/l during four short dwell exchanges (dwell time 1.5 h)
Study: 1361781
Drug: Ciprofloxacin 100
Normalized name: ciprofloxacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 100 mg/l in the last-bag
Study: 1361781
Drug: Ciprofloxacin 25
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 25 mg/l in the last-bag
Study: 6368563
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment in a plaster cast
Study: 31494621
Drug: Antibiotics (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (specific type and dosage not mentioned)
Study: 29214507
Drug: Bemiparin once
Normalized name: bemiparin
DrugBank: Bemiparin (DB09258)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bemiparin once daily
Study: 29214507
Drug: Enoxaparin twice
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin twice daily
Study: 24689456
Drug: Gluten (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten (16 g/day)
Study: 24689456
Drug: Whey (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey (16 g/day)
Study: 20624011
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg p.o. bi-daily for 4 months)
Study: 12400431
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and oral administration of Huo Xue Ming Mu Decoction
Study: 6407052
Drug: Fusaric acid
Normalized name: Fumaric Acid
DrugBank: Fumaric acid (DB01677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusaric acid plus L-dopa
Study: 30403402
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil extended-release (GE-XR) 600 mg twice a day
Study: 29729860
Drug: Ventilatory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilatory therapy combined with exercise training (V+ET)
Study: 29729860
Drug: Ventilatory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilatory therapy combined with exercise training (V+ET) in subjects with central sleep apnoea (CSA)
Study: 29729860
Drug: Ventilatory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilatory therapy combined with exercise training (V+ET) in subjects with obstructive sleep apnoea (OSA)
Study: 22228539
Drug: 453 g
Normalized name: levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 453 g concentrate (T1)
Study: 22228539
Drug: 342 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 342 g concentrate + 74 g lupin seed (T2)
Study: 22228539
Drug: 228 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 228 g concentrate + 147 g lupin seed (T3)
Study: 22228539
Drug: 116 g
Normalized name: STANNOUS FLUORIDE 0.116 g in 120 g DENTAL GEL [Burkhart]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 116 g concentrate + 219 g lupin seed (T4)
Study: 22228539
Drug: 290 g
Normalized name: MARINE COLLAGEN, SOLUBLE 290 g in 1000 mL / HYALURONIC ACID 10 g in 1000 mL / CERAMIDE NP 20 g in 1000 mL / ASCORBIC ACID, (-)- 480 g in 1000 mL TOPICAL SOLUTION [Anti Aging Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 290 g lupin seed (T5)
Study: 19737630
Drug: Reference solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference solution (glucose solution)
Study: 17517820
Drug: Pharmacotherapy (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (specific medications not detailed)
Study: 17517820
Drug: No pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pharmacotherapy (Control)
Study: 8540119
Drug: Cisplatin high
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin high dose (100 mg/m2 i.v. day 1) + Etoposide (100 mg/m2 i.v. days 4, 6, and 8)
Study: 8540119
Drug: Cisplatin low
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin low dose (60 mg/m2 day 1) + Etoposide (100 mg/m2 i.v. days 4, 6, and 8)
Study: 8540119
Drug: Cisplatin high
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin high dose (100 mg/m2 i.v. day 1)
Study: 8540119
Drug: Cisplatin low
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin low dose (60 mg/m2 day 1)
Study: 27809622
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate plus isosorbide mononitrate 10 mg vaginal tablets
Study: 27809622
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100 mg daily plus placebo vaginal tablets
Study: 25165161
Drug: Inactivated Influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated Influenza Vaccine (IIV) followed by Live Attenuated Influenza Vaccine (LAIV)
Study: 25165161
Drug: Live Attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live Attenuated Influenza Vaccine (LAIV) followed by Live Attenuated Influenza Vaccine (LAIV)
Study: 25165161
Drug: Initial dose
Normalized name: PEANUT ALLER INITIAL DOSE ORAL,PKT,13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of Live Attenuated Influenza Vaccine (LAIV)
Study: 22130166
Drug: Ipilimumab and
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab and vaccine
Study: 19625327
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for mixed urinary incontinence (MUI)
Study: 19625327
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment for mixed urinary incontinence (MUI)
Study: 3255829
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg trimethoprim
Study: 3255829
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trimethoprim
Study: 3255829
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg trimethoprim
Study: 3255829
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (5-7 days)
Study: 22010544
Drug: MF59 adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59 adjuvanted influenza vaccine
Study: 22010544
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine without MF59 adjuvant
Study: 18647573
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (Control)
Study: 16463410
Drug: Traditional Treatment
Normalized name: Midol Traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Treatment Model (TTM)
Study: 12771254
Drug: 50 mg/d
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/d pregabalin
Study: 12771254
Drug: 150 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/d pregabalin
Study: 12771254
Drug: 300 mg/d
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/d pregabalin
Study: 12771254
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d pregabalin
Study: 1301409
Drug: Acetyl‐L‐carnitine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl‐L‐carnitine (3 x 1 g daily for 1 month) + methylprednisolone (50 mg daily for 14 days)
Study: 3541062
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2‐triacetin gel (Prepidil gel) endocervically
Study: 20554740
Drug: Atenolol, bisoprolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, bisoprolol, or metoprolol (beta-blockers)
Study: 15894434
Drug: Readiness for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Readiness for treatment
Study: 2047768
Drug: Before instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before instillation therapy
Study: 31232370
Drug: Î² blockers
Normalized name: I2
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Î² blockers
Study: 25613214
Drug: Single-drug (doxorubicin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-drug (doxorubicin) chemoembolization
Study: 25613214
Drug: Double-drug (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-drug (doxorubicin and mitomycin C) chemoembolization
Study: 25613214
Drug: Triple-drug (doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug (doxorubicin, mitomycin C, and gemcitabine) chemoembolization
Study: 24300505
Drug: Prehospital thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehospital thrombolysis using intravenous recombinant tissue plasminogen activator (iv rtPA, alteplase, Actilyse) with STEMO care
Study: 16507428
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of enalapril (mean: 42 ± 19.3 mg/day)
Study: 16507428
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of enalapril (mean: 17.9 ± 4.3 mg/day)